Research spending on nanotechnology risks is woefully inadequate and industry participation in data gathering projects has been limited, according to the Wilson Center’s Project on Emerging Nanotechnologies.
Nanotechnology’s promise will ‘crumble to ashes’ if regulation doesn’t ensure products are safe before reaching the market, according to a Swedish MEP.
The FDA must recognise that the size of a particle may affect its behavior and call for compulsory safety testing and labelling of nanoparticles in cosmetics, according to a US consumer group.
